Background: CHS-1420 is being developed as a proposed biosimilar to adalimumab for the treatment of rheumatoid arthritis, plaque psoriasis (PsO), and other auto-immune diseases. Objectives: This phase 3, randomized, double-blind, active-controlled, multicenter study evaluated the equivalence of CHS-1420 to adalimumab in patients with active, moderate-severe, chronic plaque PsO, including patients with psoriatic arthritis (PsA). Methods: Male and female patients (aged ≥18 years) were randomized to CHS-1420 or adalimumab. Patients received 40 mg x 2 on Day 0 and then 40 mg every other week (QOW) by subcutaneous injection. To establish the equivalence of CHS-1420 to adalimumab, the 95% CI of the treatment difference for the primary endpoint, PASI75 at Week 12, had to be within pre-specified equivalence margins of ±15%. The 55-week study is ongoing, and blinded efficacy data at Week 12 and safety data through Week 16 are available. The study was not powered for statistical analysis of the PsA subgroup. Patients with PsA were evaluated based on change in the Health Assessment Questionnaire -Disability Index (HAQ-DI) and highly sensitive C-reactive protein (hs-CRP).
OP0221 RADIOGRAPHIC PROGRESSION OF STRUCTURAL JOINT DAMAGE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH IXEKIZUMAB OVER 52 WEEKS
D. van Objectives: To assess progression of structural joint damage in PsA pts with IXE for up to 52 wks. Methods: Biologic DMARD-naïve pts with active PsA (N=417) entered into SPIRIT-P1 (NCT01695239), a double-blind phase 3 trial. Pts must have had ≥1 joint erosion on the hand and foot x-rays confirmed by central reading or had a C-reactive protein level >6 mg/L at screening. 417 pts were randomized to IXE 80 mg every 2 wks (Q2W; N=103) or 4 wks (Q4W; N=107) following a 160 mg initial dose, PBO (N=106), or adalimumab 40 mg every 2 wks (ADA; active reference arm; N=101) for 24 wks. In the Extension Period (EXT: Wks 24-52), PBO and ADA pts were re-randomized (1:1) to IXEQ2W or IXEQ4W at Wk 16 (inadequate responders) or Wk 24; ADA pts underwent a washout prior to IXE treatment. All pts were assessed for structural joint damage using the van der Heijde modified PsA Total Sharp Score (mTSS, 0-528 scale). X-rays at Wks 0, 24 and 52 were scored independently by 2 readers blinded to timepoint and clinical data (average of readers). mTSS was excluded from the pre-specified analysis if the radiograph was taken after the scheduled visit date. In a post-hoc analysis, mTSS from a radiograph taken after the scheduled visit date was interpolated and considered as observed data. Any missing data at Wk 52, in either presentation, were imputed using a linear extrapolation if they had at least 1 post-baseline value. Results: Pts had active PsA at Week 0 (Table) . 381 pts (91.3%) entered the EXT, with 374 (98.2%) having radiographs collected during the EXT. Wk 52 mean (SD) mTSS change from baseline were 0.54 (2.11) and 0.09 (1.0) for pts randomized to IXEQ4W and IXEQ2W at baseline, respectively. Similar changes at Wk 52 were obtained with the post-hoc analysis (Table) . The majority of IXEQ2W or IXEQ4W pts exhibited no structural progression through 1 year of IXE treatment (Figure) . In pts who switched from PBO or ADA to IXE, Wk 52 mean change from baseline mTSS values scores ranged from -0.03 to 0.41 (Table) . ]) with this symptom at BL. BL, baseline; DAS28-CRP, 28-joint disease activity score using C-reactive protein; HAQ-DI, health assessment questionnaire-disability index; LS, least squares; N, number of pts randomised; PASI, psoriasis area and severity index; SE, standard error; SF-36 PCS, short form-36 physical component summary.
Conclusions:
Secukinumab 300 and 150 mg provided sustained improvements in signs and symptoms and multiple clinical domains of active PsA through 2 years of therapy. Secukinumab was well tolerated, with a safety profile consistent with that reported previously.
